Can Fite Biofarma (XTAE:CANF) 12-1 Month Momentum % : 27.27% (As of Apr. 29, 2024)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma 12-1 Month Momentum %?

12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-29), Can Fite Biofarma's 12-1 Month Momentum % is 27.27%.

The industry rank for Can Fite Biofarma's 12-1 Month Momentum % or its related term are showing as below:

XTAE:CANF's 12-1 Month Momentum % is ranked better than
78.89% of 1478 companies
in the Biotechnology industry
Industry Median: -20.775 vs XTAE:CANF: 27.27

Competitive Comparison of Can Fite Biofarma's 12-1 Month Momentum %

For the Biotechnology subindustry, Can Fite Biofarma's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's 12-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's 12-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's 12-1 Month Momentum % falls into.

Can Fite Biofarma (XTAE:CANF) 12-1 Month Momentum % Calculation

12-1 Month Momentum % is calculated as following:

12-1 Month Momentum %

( Price 1-month ago

Price 12-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Can Fite Biofarma (XTAE:CANF) 12-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Can Fite Biofarma 12-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (XTAE:CANF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » 12-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).